Fabris C, Farini R, del Favero G, Piccoli A, Naccarato R
Hepatogastroenterology. 1981 Dec;28(6):316-8.
The so-called "plasma" ribonuclease (RNase), described as increased in most patients with pancreatic cancer, was studied in the blood of 92 subjects utilizing the method of Reddi and Holland, to evaluate its reliability in detecting pancreatic tumors. A significant increase of "plasma" RNase was found in pancreatic cancer (p less than 0.01) as compared with controls, non-calcifying chronic pancreatitis (p less than 0.01), calcifying chronic pancreatitis (p less than 0.01), and chronic recurrent pancreatitis (p less than 0.01). Nevertheless increased "plasma" RNase activity was also found in 18/43 patients with chronic pancreatitis, as well as in the majority of the non-pancreatic malignant tumors studied. Furthermore, in 2 out of 22 subjects with pancreatic cancer the enzyme activity was found to be normal. These data suggest that increased "plasma" RNase, although very frequent in pancreatic cancer, is not a marker of pancreatic malignancy.
所谓的“血浆”核糖核酸酶（RNase），在大多数胰腺癌患者中被描述为升高，本研究采用雷迪（Reddi）和霍兰德（Holland）的方法，对92名受试者的血液进行了检测，以评估其在检测胰腺肿瘤方面的可靠性。与对照组、非钙化性慢性胰腺炎（p＜0.01）、钙化性慢性胰腺炎（p＜0.01）和慢性复发性胰腺炎（p＜0.01）相比，胰腺癌患者的“血浆”RNase显著升高（p＜0.01）。然而，在43例慢性胰腺炎患者中的18例以及大多数所研究的非胰腺恶性肿瘤患者中，也发现“血浆”RNase活性升高。此外，在22例胰腺癌患者中有2例酶活性正常。这些数据表明，“血浆”RNase升高虽然在胰腺癌中非常常见，但并非胰腺恶性肿瘤的标志物。
